AFX 3721

The lead drug candidate from a novel series of potent anti-inflammatory small molecules that inhibit the activity of IL-4 and IL-13. Both of these pro-inflammatory cytokines are produced by Type 2 helper T cells that are over activated in many atopic disorders. IL-4 and IL-13 are the most important cytokine mediators in what is termed as type II hypersensitivity (or cytotoxic hypersensitivity), a process that drives many diseases including atopic dermatitis.